Page 212 - 2021_03-Haematologica-web

V. Wiebking et al.
induced by tonic signaling of chimeric anti-
gen receptors. Nat Med. 2015;21(6):581-590. 40. Osborn MJ, Webber BR, Knipping F, et al. Evaluation of TCR gene editing achieved by TALENs, CRISPR/Cas9, and megaTAL
nucleases. Mol Ther. 2016;24(3):570-581. 41. Vakulskas CA, Dever DP, Rettig GR, et al. A high-fidelity Cas9 mutant delivered as a ribonucleoprotein complex enables efficient gene editing in human hematopoietic stem and progenitor cells. Nat Med.
2018;24(8):1216-1224.
42. Hendel A, Bak RO, Clark JT, et al.
Chemically modified guide RNAs enhance CRISPR-Cas genome editing in human pri- mary cells. Nat Biotechnol. 2015;33(9):985- 989.
43. Qasim W. Allogeneic CAR T cell therapies for leukemia. Am J Hematol. 2019;94 (S1):S50-S54.
44. Ghosh A, Smith M, James SE, et al. Donor CD19 CAR T cells exert potent graft-versus- lymphoma activity with diminished graft- versus-host activity. Nat Med. 2017;23(2): 242-249.
45. Poirot L, Philip B, Schiffer-Mannioui C, et al. Multiplex genome-edited T-cell manufactur- ing platform for “off-the-shelf” adoptive T- cell immunotherapies. Cancer Res. 2015;75 (18):3853-3864.
46. Qasim W, Zhan H, Samarasinghe S, et al. Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells. Sci Transl Med. 2017;9(374).
47. Barrett DM, Seif AE, Carpenito C, et al. Noninvasive bioluminescent imaging of pri- mary patient acute lymphoblastic leukemia: a strategy for preclinical modeling. Blood. 2011;118(15):e112-e117.
48.Sano H, Mochizuki K, Kobayashi S, et al. Two occurrences of leukemia relapse due to mismatched HLA loss after haploidentical stem cell transplantation from different fam- ily donors with KIR ligand mismatch. J Pediatr Hematol Oncol. 2020;42(2):e104- e106.
49. Christopher MJ, Petti AA, Rettig MP, et al.
Immune escape of relapsed AML cells after allogeneic transplantation. N Engl J Med. 2018;379(24):2330-2341.
50. Vago L, Perna SK, Zanussi M, et al. Loss of mismatched HLA in leukemia after stem-cell transplantation. N Engl J Med. 2009;361 (5):478-488.
51.Kenderian SS, Porter DL, Gill S. Chimeric antigen receptor T cells and hematopoietic cell transplantation: how not to put the CART before the horse. Biol Blood Marrow Transplant. 2017;23(2):235-246.
52. Park JH, Rivière I, Gonen M, et al. Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N Engl J Med. 2018;378(5):449-459.
53. Maude SL, Frey N, Shaw PA, et al. Chimeric antigen receptor T cells for sustained remis- sions in leukemia. N Engl J Med. 2014;371 (16):1507-1517.
54. Luznik L, Fuchs EJ. High-dose, post-trans- plantation cyclophosphamide to promote graft-host tolerance after allogeneic hematopoietic stem cell transplantation. Immunol Res. 2010;47(1-3):65-77.
55. Luznik L, Bolaños-Meade J, Zahurak M, et al. High-dose cyclophosphamide as single- agent, short-course prophylaxis of graft-ver- sus-host disease. Blood. 2010;115(16): 3224- 3230.
56. Hoffmann J-M, Schubert M-L, Wang L, et al. Differences in expansion potential of naive chimeric antigen receptor T cells from healthy donors and untreated chronic lym- phocytic leukemia patients. Front Immunol. 2018;8:1956.
57. Chongsathidkiet P, Jackson C, Koyama S, et al. Sequestration of T cells in bone marrow in the setting of glioblastoma and other intracranial tumors. Nat Med. 2018;24(9): 1459-1468.
58. Qin H, Ishii K, Nguyen S, et al. Murine Pre- B cell ALL induces T cell dysfunction not fully reversed by introduction of a chimeric antigen receptor. Blood. 2018;132(18):1899- 1910.
59. Knaus HA, Berglund S, Hackl H, et al.
Signatures of CD8+ T cell dysfunction in AML patients and their reversibility with response to chemotherapy. JCI Insight. 2018;3(21).
60. Dai H, Zhang W, Li X, et al. Tolerance and efficacy of autologous or donor-derived T cells expressing CD19 chimeric antigen receptors in adult B-ALL with extramedullary leukemia. Oncoimmunology. 2015;4(11): e1027469.
61. Yang Y, Kohler ME, Chien CD, et al. TCR engagement negatively affects CD8 but not CD4 CAR T cell expansion and leukemic clearance. Sci Transl Med. 2017;9(417).
62. Zhao J, Song Y, Liu D. Clinical trials of dual- target CAR T cells, donor-derived CAR T cells, and universal CAR T cells for acute lymphoid leukemia. J Hematol Oncol. 2019;12(1):17.
63. Torikai H, Reik A, Liu P-Q, et al. A founda- tion for universal T-cell based immunother- apy: T cells engineered to express a CD19- specific chimeric-antigen-receptor and elim- inate expression of endogenous TCR. Blood. 2012;119(24):5697-5705.
64. Torikai H, Reik A, Soldner F, et al. Toward eliminating HLA class I expression to gener- ate universal cells from allogeneic donors. Blood. 2013;122(8):1341-1349.
65. Ren J, Liu X, Fang C, Jiang S, June CH, Zhao Y. Multiplex genome editing to generate uni- versal CAR T cells resistant to PD1 inhibi- tion. Clin Cancer Res. 2017;23(9):2255-2266.
66. Gornalusse GG, Hirata RK, Funk SE, et al. HLA-E-expressing pluripotent stem cells escape allogeneic responses and lysis by NK cells. Nat Biotechnol. 2017;35(8):765-772.
67. Brudno JN, Lam N, Vanasse D, et al. Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma. Nat Med. 2020;26(2):270-280.
68. Zhou X, Dotti G, Krance RA, et al. Inducible caspase-9 suicide gene controls adverse effects from alloreplete T cells after hap- loidentical stem cell transplantation. Blood. 2015;125(26):4103-4113.
858
haematologica | 2021; 106(3)